ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Takara Bio, Inc.

Business Summary

Takara Bio, Inc. engages in development and marketing of genetic engineering technologies. It provides products and services for basic research and industrial application in life sciences. These include services for the research and manufacturing of regenerative medicine products and the development of gene therapy products for synovial sarcoma. It also develops, manufactures, and sells reagents for polymerase chain reaction (PCR) tests for COVID-19. The company was founded on April 1, 2002 and is headquartered in Kusatsu, Japan.

Financial Highlights

Mar 2022 JPYUSD
Gross Profit48,179M428.74M
Operating income28,902M257.19M
Income before tax27,532M245.00M
Net income19,850M176.64M
Diluted EPS164.831.46
Dividends Per Share330.29
Total Assets115,712M953.34M
Total liabilities19,646M161.86M
Total equity95,873M789.89M
Operating cash flow6,985M62.15M
Currency in JPYCurrency in USD

Historical Data

 Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Revenue 32,312M 35,841M 34,565M 46,086M 67,699M
Gross Profit 18,079M 20,179M 20,519M 30,909M 48,179M
Operating income 3,556M 5,465M 6,276M 13,953M 28,902M
Income before tax 3,361M 4,823M 5,433M 13,552M 27,532M
Net income 2,335M 3,658M 3,820M 9,547M 19,850M
EBITDA 6,773M 8,840M 9,806M 17,739M 33,051M
Diluted EPS 19.39 30.37 31.71 79.28 164.83
Dividends Per Share 4.50 7 8 16 33
Total Assets 70,237M 72,517M 76,343M 90,982M 115,712M
Total liabilities 8,278M 8,421M 9,751M 16,678M 19,646M
Total equity 61,853M 64,010M 66,496M 74,182M 95,873M
Operating cash flow 3,935M 5,783M 6,339M 13,943M 6,985M
 Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Revenue 291.53M 323.19M 317.90M 434.53M 602.45M
Gross Profit 163.12M 181.96M 188.72M 291.43M 428.74M
Operating income 32.08M 49.28M 57.72M 131.56M 257.19M
Income before tax 30.32M 43.49M 49.96M 127.77M 245.00M
Net income 21.06M 32.98M 35.13M 90.01M 176.64M
EBITDA 61.11M 79.71M 90.19M 167.25M 294.11M
Diluted EPS 0.17 0.27 0.29 0.74 1.46
Dividends Per Share 0.04 0.06 0.07 0.15 0.29
Total Assets 660.43M 655.16M 707.17M 823.36M 953.34M
Total liabilities 77.83M 76.08M 90.32M 150.93M 161.86M
Total equity 581.59M 578.30M 615.96M 671.33M 789.89M
Operating cash flow 35.50M 52.14M 58.30M 131.46M 62.15M

Valuation Measures

Mar 2022
Operating margin42.69%
Profit margin29.32%

Key executives

  • President & Representative Director: Koichi Nakao
  • COO, Director & Senior Managing Executive Officer: Junichi Mineno
  • CFO, Representative Director & Executive VP: Shuichiro Matsuzaki
  • Executive Officer & GM-Business Administration: Takuya Kakemi
  • Executive Officer & Manager-CDM Center 4: Masanari Kitagawa


  • Takara Holdings, Inc. (60.9%)
  • Nomura Asset Management Co., Ltd. (1.6%)
  • JPMorgan Asset Management (Asia Pacific) Ltd. (1.2%)
  • The Vanguard Group, Inc. (1.0%)
  • Nikko Asset Management Co., Ltd. (0.6%)
  • Daiwa Asset Management Co. Ltd. (0.6%)
  • Norges Bank Investment Management (0.5%)
  • BlackRock Fund Advisors (0.5%)
  • The Bank of Kyoto, Ltd. (0.4%)
  • Dai-ichi Life Holdings, Inc. (0.4%)

Contact Details

Related Companies

  • Cellectis AB
  • Takara Korea Biomedical, Inc.
  • Takara Biomedical Technology (Beijing) Co., Ltd.
  • TaKara Biotechnology (Dalian) Co., Ltd.
  • Takara Bio USA Holdings, Inc.
  • M's Science Corp. /Anti-Cancer Drug Division/
  • Takara Bio Europe SAS
  • Takara Bio Employee Stock Ownership Plan
  • Takara Bio Europe AB
  • Takara Bio USA, Inc.


  • Alaunos Therapeutics, Inc.
  • Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh
  • Vaxart, Inc.
Last Updated on 28 Nov, 2022

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more